Skip to main content
Premium Trial:

Request an Annual Quote

Facing Nasdaq Delisting, Hybridon Plans One-for-Five Reverse Stock Split


CAMBRIDGE, Mass.--Hybridon, a genetically based drug discovery company here, has filed with the US Securities and Exchange Commission for a one-for-five reverse stock split, which would shrink the company's outstanding shares from about 25 million to 5 million. The plan, which will be presented to shareholders at a special meeting November 18, was proposed to help the company continue to meet Nasdaq listing requirements.

Last month, the exchange notified Hybridon of impending delisting, however, the company has appealed and its stock continues to be traded pending the outcome. Hybridon has expressed concern that delisting could adversely affect its liquidity and ability to raise capital.

Filed under

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.